根据ESI于2026年1月发布的数据，我校高被引论文（Highly Cited Papers）691篇，热点论文（Hot Papers）29篇，见附件：2026年1月南方医科大学高被引论文及热点论文简表。详情如下。
从学科角度看，在691篇高被引论文中，临床医学最多（348篇），占比50.36%，药理学与毒理学54篇（7.81%）紧跟其后。
|
序号 |
高被引论文 Research Field |
2026.1 |
2025.11 |
||
|
论文数 |
占比 |
论文数 |
占比 |
||
|
CLINICAL MEDICINE |
348 |
50.36% |
332 |
50.23% |
|
|
2 |
MOLECULAR BIOLOGY & GENETICS |
49 |
7.09% |
46 |
6.96% |
|
3 |
BIOLOGY & BIOCHEMISTRY |
49 |
7.09% |
45 |
6.81% |
|
4 |
PHARMACOLOGY & TOXICOLOGY |
54 |
7.81% |
56 |
8.47% |
|
5 |
MATERIALS SCIENCE |
39 |
5.64% |
38 |
5.75% |
|
6 |
NEUROSCIENCE & BEHAVIOR |
21 |
3.04% |
21 |
3.18% |
|
7 |
ENGINEERING |
12 |
1.74% |
11 |
1.66% |
|
8 |
MICROBIOLOGY |
21 |
3.04% |
20 |
3.03% |
|
9 |
CHEMISTRY |
8 |
1.16% |
10 |
1.51% |
|
10 |
PHYSICS |
30 |
4.34% |
25 |
3.78% |
|
11 |
PSYCHIATRY/PSYCHOLOGY |
12 |
1.74% |
12 |
1.82% |
|
12 |
IMMUNOLOGY |
15 |
2.17% |
12 |
1.82% |
|
13 |
SOCIAL SCIENCES, GENERAL |
7 |
1.01% |
9 |
1.36% |
|
14 |
COMPUTER SCIENCE |
10 |
1.45% |
9 |
1.36% |
|
15 |
AGRICULTURAL SCIENCES |
5 |
0.72% |
5 |
0.76% |
|
16 |
MULTIDISCIPLINARY |
1 |
0.14% |
0 |
0.00% |
|
17 |
ENVIRONMENT/ECOLOGY |
9 |
1.30% |
9 |
1.36% |
|
18 |
MATHEMATICS |
1 |
0.14% |
1 |
0.15% |
|
|
合计 |
691 |
100.00% |
661 |
100.00% |
|
序号 |
2026年1月我校29篇热点论文 标题 |
来源期刊 |
DOI |
Research Field |
Times Cited |
|
1 |
MINIMAL INFORMATION FOR STUDIES OF EXTRACELLULAR VESICLES (MISEV2023): FROM BASIC TO ADVANCED APPROACHES |
JOURNAL OF EXTRACELLULAR VESICLES 13 (2): - FEB 2024 |
10.1002/jev2.12404 |
BIOLOGY & BIOCHEMISTRY |
1446 |
|
2 |
GLOBAL BURDEN OF 288 CAUSES OF DEATH AND LIFE EXPECTANCY DECOMPOSITION IN 204 COUNTRIES AND TERRITORIES AND 811 SUBNATIONAL LOCATIONS, 1990-2021: A SYSTEMATIC ANALYSIS FOR THE GLOBAL BURDEN OF DISEASE STUDY 2021 |
LANCET 403 (10440): 2100-2132 MAY 18 2024 |
10.1016/S0140-6736(24)00367-2 |
CLINICAL MEDICINE |
1231 |
|
3 |
GLOBAL BURDEN AND STRENGTH OF EVIDENCE FOR 88 RISK FACTORS IN 204 COUNTRIES AND 811 SUBNATIONAL LOCATIONS, 1990-2021: A SYSTEMATIC ANALYSIS FOR THE GLOBAL BURDEN OF DISEASE STUDY 2021 |
LANCET 403 (10440): 2162-2203 MAY 18 2024 |
10.1016/S0140-6736(24)00933-4 |
CLINICAL MEDICINE |
1184 |
|
4 |
GLOBAL INCIDENCE, PREVALENCE, YEARS LIVED WITH DISABILITY (YLDS), DISABILITY-ADJUSTED LIFE-YEARS (DALYS), AND HEALTHY LIFE EXPECTANCY (HALE) FOR 371 DISEASES AND INJURIES IN 204 COUNTRIES AND TERRITORIES AND 811 SUBNATIONAL LOCATIONS, 1990-2021: A SYSTEMATIC ANALYSIS FOR THE GLOBAL BURDEN OF DISEASE STUDY 2021 |
LANCET 403 (10440): 2133-2161 MAY 18 2024 |
10.1016/S0140-6736(24)00757-8 |
CLINICAL MEDICINE |
813 |
|
5 |
BURDEN OF DISEASE SCENARIOS FOR 204 COUNTRIES AND TERRITORIES, 2022-2050: A FORECASTING ANALYSIS FOR THE GLOBAL BURDEN OF DISEASE STUDY 2021 |
LANCET 403 (10440): 2204-2256 MAY 18 2024 |
10.1016/S0140-6736(24)00685-8 |
CLINICAL MEDICINE |
394 |
|
6 |
GLOBAL, REGIONAL, AND NATIONAL BURDEN OF STROKE AND ITS RISK FACTORS, 1990-2021: A SYSTEMATIC ANALYSIS FOR THE GLOBAL BURDEN OF DISEASE STUDY 2021 |
LANCET NEUROLOGY 23 (10): 973-1003 OCT 2024 |
10.1016/S1474-4422(24)00369-7 |
NEUROSCIENCE & BEHAVIOR |
368 |
|
7 |
USING CLUSTERPROFILER TO CHARACTERIZE MULTIOMICS DATA |
NATURE PROTOCOLS 19 (11): - NOV 2024 |
10.1038/s41596-024-01020-z |
BIOLOGY & BIOCHEMISTRY |
314 |
|
8 |
GLOBAL, REGIONAL, AND NATIONAL PREVALENCE OF ADULT OVERWEIGHT AND OBESITY, 1990-2021, WITH FORECASTS TO 2050: A FORECASTING STUDY FOR THE GLOBAL BURDEN OF DISEASE STUDY 2021 |
LANCET 405 (10481): 813-838 MAR 8 2025 |
10.1016/S0140-6736(25)00355-1 |
CLINICAL MEDICINE |
215 |
|
9 |
ALECTINIB IN RESECTED <I>ALK</I>-POSITIVE NON-SMALL-CELL LUNG CANCER |
NEW ENGLAND JOURNAL OF MEDICINE 390 (14): 1265-1276 APR 11 2024 |
10.1056/NEJMoa2310532 |
CLINICAL MEDICINE |
201 |
|
10 |
GLOBAL FERTILITY IN 204 COUNTRIES AND TERRITORIES, 1950-2021, WITH FORECASTS TO 2100: A COMPREHENSIVE DEMOGRAPHIC ANALYSIS FOR THE GLOBAL BURDEN OF DISEASE STUDY 2021 |
LANCET 403 (10440): 2057-2099 MAY 18 2024 |
10.1016/S0140-6736(24)00550-6 |
CLINICAL MEDICINE |
195 |
|
11 |
THE CHINESE SOCIETY OF CLINICAL ONCOLOGY (CSCO): CLINICAL GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF GASTRIC CANCER, 2023 |
CANCER COMMUNICATIONS : - DEC 31 2023 |
10.1002/cac2.12516 |
CLINICAL MEDICINE |
180 |
|
12 |
PULMONARY HYPERTENSION |
NATURE REVIEWS DISEASE PRIMERS 10 (1): - JAN 4 2024 |
10.1038/s41572-023-00486-7 |
CLINICAL MEDICINE |
147 |
|
13 |
GLOBAL BURDEN OF METABOLIC DISEASES, 1990-2021021 |
METABOLISM-CLINICAL AND EXPERIMENTAL 160: - NOV 2024 |
10.1016/j.metabol.2024.155999 |
BIOLOGY & BIOCHEMISTRY |
128 |
|
14 |
TORIPALIMAB PLUS CHEMOTHERAPY FOR RECURRENT OR METASTATIC NASOPHARYNGEAL CARCINOMA THE JUPITER-02 RANDOMIZED CLINICAL TRIAL |
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION 330 (20): 1961-1970 NOV 28 2023 |
10.1001/jama.2023.20181 |
CLINICAL MEDICINE |
127 |
|
15 |
SINGLE-CELL TRANSCRIPTOME ANALYSIS REVEALS THE ASSOCIATION BETWEEN HISTONE LACTYLATION AND CISPLATIN RESISTANCE IN BLADDER CANCER |
DRUG RESISTANCE UPDATES 73: - MAR 2024 |
10.1016/j.drup.2024.101059 |
PHARMACOLOGY & TOXICOLOGY |
104 |
|
16 |
IMLGAM: INTEGRATED MACHINE LEARNING AND GENETIC ALGORITHM-DRIVEN MULTIOMICS ANALYSIS FOR PAN-CANCER IMMUNOTHERAPY RESPONSE PREDICTION |
IMETA 4 (2): - APR 2025 |
10.1002/imt2.70011 |
MICROBIOLOGY |
91 |
|
17 |
BURDEN OF DISEASE ATTRIBUTABLE TO HIGH BODY MASS INDEX: AN ANALYSIS OF DATA FROM THE GLOBAL BURDEN OF DISEASE STUDY 2021 |
ECLINICALMEDICINE 76: - OCT 2024 |
10.1016/j.eclinm.2024.102848 |
CLINICAL MEDICINE |
89 |
|
18 |
THE OSTEOARTHRITIS |
NATURE REVIEWS DISEASE PRIMERS 11 (1): - FEB 13 2025 |
10.1038/s41572-025-00594-6 |
CLINICAL MEDICINE |
79 |
|
19 |
MONASCUS PIGMENT-PROTECTED BONE MARROW-DERIVED STEM CELLS FOR HEART FAILURE TREATMENT |
BIOACTIVE MATERIALS 42: 270-283 DEC 2024 |
10.1016/j.bioactmat.2024.08.038 |
MATERIALS SCIENCE |
76 |
|
20 |
TRANSARTERIAL CHEMOEMBOLISATION COMBINED WITH LENVATINIB PLUS PEMBROLIZUMAB VERSUS DUAL PLACEBO FOR UNRESECTABLE, NON-METASTATIC HEPATOCELLULAR CARCINOMA (LEAP-012) : A MULTICENTRE, RANDOMISED, DOUBLE-BLIND, PHASE 3 STUDY |
LANCET 405 (10474): 203-215 JAN 18 2025 |
10.1016/S0140-6736(24)02575-3 |
CLINICAL MEDICINE |
72 |
|
21 |
TISSUE MACROPHAGES: ORIGIN, HETEROGENITY, BIOLOGICAL FUNCTIONS, DISEASES AND THERAPEUTIC TARGETS |
SIGNAL TRANSDUCTION AND TARGETED THERAPY 10 (1): - MAR 7 2025 |
10.1038/s41392-025-02124-y |
MOLECULAR BIOLOGY & GENETICS |
62 |
|
22 |
A METALLIC ROOM-TEMPERATURE D-WAVE ALTERMAGNET |
NATURE PHYSICS 21 (5): - MAY 2025 |
10.1038/s41567-025-02822-y |
PHYSICS |
50 |
|
23 |
MICROSCALE FIBER PHOTOACOUSTIC SPECTROSCOPY FOR <I>IN SITU</I> AND REAL-TIME TRACE GAS SENSING |
ADVANCED PHOTONICS 6 (6): - NOV 1 2024 |
10.1117/1.AP.6.6.066008 |
PHYSICS |
33 |
|
24 |
SINGLE-CELL AND SPATIAL TRANSCRIPTOME ANALYSES REVEAL TERTIARY LYMPHOID STRUCTURES LINKED TO TUMOUR PROGRESSION AND IMMUNOTHERAPY RESPONSE IN NASOPHARYNGEAL CARCINOMA |
NATURE COMMUNICATIONS 15 (1): - SEP 4 2024 |
10.1038/s41467-024-52153-4 |
MULTIDISCIPLINARY |
31 |
|
25 |
MULTIFUNCTIONAL DNA HYDROGELS WITH LIGHT-TRIGGERED GAS-THERAPY AND CONTROLLED G-EXOS RELEASE FOR INFECTED WOUND HEALING |
BIOACTIVE MATERIALS 52: 422-437 OCT 2025 |
10.1016/j.bioactmat.2025.06.004 |
MATERIALS SCIENCE |
14 |
|
26 |
EFFECT OF DAPAGLIFLOZIN ON METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS: MULTICENTRE, DOUBLE BLIND, RANDOMISED, PLACEBO CONTROLLED TRIAL |
BMJ-BRITISH MEDICAL JOURNAL 389: - JUN 4 2025 |
10.1136/bmj-2024-083735 |
CLINICAL MEDICINE |
12 |
|
27 |
PECTIN-TYPE POLYSACCHARIDES FROM RASPBERRY (RUBUS IDAEUS L.): STRUCTURE CHARACTERIZATION AND ACTIVITY AGAINST DSS-INDUCED COLITIS |
CARBOHYDRATE POLYMERS 364: - SEP 15 2025 |
10.1016/j.carbpol.2025.123710 |
CHEMISTRY |
11 |
|
28 |
GLOBAL, REGIONAL, AND NATIONAL TRENDS IN ROUTINE CHILDHOOD VACCINATION COVERAGE FROM 1980 TO 2023 WITH FORECASTS TO 2030: A SYSTEMATIC ANALYSIS FOR THE GLOBAL BURDEN OF DISEASE STUDY 2023 |
LANCET 406 (10500): 235-260 JUL 15 2025 |
10.1016/S0140-6736(25)01037-2 |
CLINICAL MEDICINE |
11 |
|
29 |
THE THREAT OF MICROPLASTICS TO HUMAN KIDNEY HEALTH: MECHANISMS OF NEPHROTOXICITY AND FUTURE RESEARCH DIRECTIONS |
ENVIRONMENTAL RESEARCH 283: - OCT 15 2025 |
10.1016/j.envres.2025.122124 |
ENVIRONMENT/ECOLOGY |
4 |
